The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Targeting NF-κB in hematologic malignancies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Bortezomib was evaluated in several clinical trials in relapsed and refractory MM, yielding response rates from 30 to 40%.(90,91) Bortezomib is approved by the FDA and by the European Regulatory Agency (EMEA) for the treatment of MM.”
BackgroundProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Cited by
Regulation and Function of NF-κB Transcription Factors in the Immune System
Vallabhapurapu, S., & Karin, M. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132641 · Cited by 2,588
Involvement of linear polyubiquitylation of NEMO in NF-κB activation
Tokunaga, F., Sakata, S.-I., Saeki, Y., Satomi, Y., Kirisako, T., Kamei, K., Nakagawa, T., Kato, M., Murata, S., Yamaoka, S., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1821 · Cited by 942
microRNA Regulation of Inflammatory Responses
O'Connell, R. M., Rao, D. S., & Baltimore, D. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075013 · Cited by 843
NF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies
Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., & Baltimore, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105398108 · Cited by 386
Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy
Mortezaee, K., Salehi, E., Mirtavoos‐mahyari, H., Motevaseli, E., Najafi, M., Farhood, B., Rosengren, R. J., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28122 · Cited by 340
Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes
Gonzales, A. M., & Orlando, R. A. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-17 · Cited by 260
Kiessling, M. K., Klemke, C. D., Kamiński, M. M., Galani, I. E., Krammer, P. H., & Gülow, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3221 · Cited by 115
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
Kawada, H., Kaneko, M., Sawanobori, M., Uno, T., Matsuzawa, H., Nakamura, Y., Matsushita, H., & Ando, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062717 · Cited by 55
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Ablation of miR-146b in mice causes hematopoietic malignancy
Mitsumura, T., Ito, Y., Chiba, T., Matsushima, T., Kurimoto, R., Tanaka, Y., Kato, T., Uchida, K., Ito, T., Yamamoto, K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017954 · Cited by 22
Metadata
- Authors
- Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P., & Kroemer, G.
- Venue
- Cell Death & Differentiation
- Published
- 2006-02-24
- Volume
- 13
- Issue
- 5
- Pages
- 748-758
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2035474025
- Cited by
- 158
- References
- 4
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.